M&As this week: ImmunoPrecise Antibodies, Recipharm, Bio Techne

5th January 2018 (Last Updated January 5th, 2018 00:00)

ImmunoPrecise Antibodies Ltd (IPA) has signed a binding letter of intent to purchase a 35% stake in SERPINx BV for €250,000 ($300,000).

ImmunoPrecise Antibodies Ltd (IPA) has signed a binding letter of intent to purchase a 35% stake in SERPINx BV for €250,000 ($300,000).

IPA is a Canadian integrated antibody solutions company, while SERPINx is a protein therapeutics company based in the Netherlands.

The acquisition will enable SERPINx to develop recombinant protease inhibitors for the treatment of bradykinin-mediated diseases.

Recipharm AB has purchased the remaining 26% of shares in Indian life sciences company Nitin Lifesciences Ltd for Rs2.8bn ($43.86m).

Bio Techne Corp has completed the acquisition of Atlanta Biological Inc and its affiliate Scientific Ventures Inc.

The acquisition will help Atlanta Biological to expand its products offering.

Bio Techne is a purified proteins developer based in the US, while Atlanta Biological, also based in the US, is a cell culture sea, media and reagents supplier.

Tetra Bio-Pharma Inc has agreed to purchase the remaining 20% stake in inhalation product developer PhytoPain Pharma Inc (PPP) from the entities controlled by Andre Rancourt and Guy Chamberland for C$12.42m ($9.87m).

The drug discovery company will purchase the remaining issued and outstanding common shares of Phytopain Pharma from Andre Rancourt and Guy Chamberland.

"The drug discovery company will purchase the remaining issued and outstanding common shares of Phytopain Pharma from Andre Rancourt and Guy Chamberland."

PhytoPain Pharma will become a subsidiary of Tetra Bio-Pharma upon completion of the acquisition.

The acquisition will help in expanding Tetra Bio-Pharma’s cannabinoid-based drugs pipeline.

Both companies involved are based in Canada.

United Therapeutics Corp has purchased a minority stake in biopharmaceutical company Corsair Pharma Inc.

The biotechnology company has simultaneously signed a licensing agreement for Corsair’s portfolio of patents.

Both companies involved in the acquisition are based in the US.

Biocrates Life Sciences has acquired German metabolomics biomarker developer Metanomics Health GmbH from BASF Plant Science GmbH.

The company has simultaneously raised venture financing from BASF Plant Science GmbH, MIG Fonds and GA Asset Fund GmbH & Co KG (GAF). BASF Plant Science GmbH will retain a minority share in Biocrates as part of the transaction.

Biocrates is an Austrian metabolomic biomarkers developer, while BASF Plant Science is a German plant biotechnology company.

The acquisition will enable Biocrates to provide complete solutions to the metabolomics market.